IMMIX BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
IMMIX BIOPHARMA, INC. (IMMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.47% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-05-07
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.47%.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month |
|---|---|---|
| 2026-03-31 | 3.47% 10-Q · filed 2026-05-07 | |
| 2022-06-30 | 1.70% 10-Q · filed 2022-08-12 | |
| 2022-03-31 | 1.70% 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |